CWM
ITCI

Catamount Wealth Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Catamount Wealth Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-195
Closed -$4K – 231
2018
Q3 		$4K Buy
+195
New +$4.08K ﹤0.01% 173

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Catamount Wealth Management's ITCI Position: Q4 2018 in Review

Catamount Wealth Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2018, closing a stake of 195 shares — an estimated $4K sold.

Catamount Wealth Management first reported a position in ITCI in Q3 2018 and held it in 1 quarter. The position peaked at $4K in Q3 2018. 127 funds tracked by Wall St. Rank hold ITCI as of Q4 2018.

  • Catamount Wealth Management reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2018 after selling out during the quarter.
  • Catamount Wealth Management sold 195 Intra-Cellular Therapies Inc. shares in Q4 2018, an estimated $4K.
  • Catamount Wealth Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2018 and held it in 1 quarter.
  • Catamount Wealth Management's Intra-Cellular Therapies Inc. position peaked at $4K in Q3 2018.
  • 127 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2018.

Based on Catamount Wealth Management's 13F filing for Q4 2018, filed 13 Feb 2019.